Treatment strategy for brain metastases from esophageal cancer. Issue 2 (April 2020)

• Record Type: Journal Article
• Authors: Domeki, Yasushi; Nakajima, Masanobu; Takahashi, Masakazu; Kikuchi, Maiko; Yokoyama, Haruka; Ogata, Hideo; Okamoto, Kentaro; Yamaguchi, Satoru; Sasaki, Kinro; Tsuchioka, Takashi; Kato, Hiroyuki
• Is Part Of: Tumori. Volume 106:Issue 2(2020)
• Page Start: 109
• Page End: 114
• Publication Date: 2020-04
• Subjects: Esophageal cancer -- brain metastases -- radiotherapy; Cancer -- Periodicals; 616.994
• DOI: 10.1177/0300891619869518
• Languages: English
• ISSNs: 0300-8916

Abstract

Background: This study aimed to examine the treatment outcomes of patients with brain metastases from esophageal cancer. Brain metastases from esophageal cancer are rare and have a poorer prognosis than brain metastases from lung and breast cancer. Methods: This study included patients who were diagnosed with and treated for esophageal cancer in our department and subsequently developed brain metastases between April 2010 and December 2014. We examined the differences in survival in patients based on receiving chemotherapy. Results: In total, 8 patients (7 men and 1 woman) with a mean age of 65 years (range 51–73) were included. Seven presented with neurologic symptoms. Two were diagnosed via computed tomography (CT), 5 via magnetic resonance imaging, and 1 via positron emission tomography/CT. They were treated using whole-brain irradiation or with a gamma knife. In 5 patients, chemotherapy was administered after treatment of the brain metastases. The mean survival from the start of treatment was 358 days (range 31–1196). Conclusion: The relatively successful local control of brain metastases in these patients indicates that long-term survival may be attainable via concomitant chemotherapy.